Medical News / Reported from ACC Congress 2020: Deepak Bhatt, MD: Ticagrelor and Major Adverse Limb Events

A new analysis of patients from 2 major clinical trials is providing clinicians with more insight into the benefits of ticagrelor use in patients with atherosclerosis. Using data from the randomized, double-blind PEGASUS-TIMI 54 and THEMIS trials found the use of the P2Y12 inhibitor not only reduces major adverse cardiovascular events but also cut the rate of major adverse limb events by 41%. Source: MDMag. By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization.

read more

Few surgical advances this century have had an impact equal to that of transcatheter aortic valve ... read more
While the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) ... read more
Results of a new study are offering clinicians guidance on optimal timing of menopausal hormone replacement ... read more
The clinical discussion as to whether electronic cigarette devices has already begun. But debate still wages ... read more